Role of LDH as a Predictor of Treatment Outcomes in Hepatocellular Carcinoma

Overview

Hepatocellular carcinoma represents the commonest primary cancer of the liver.serum lactate dehydrogenase is an indirect marker of tumor hypoxia,angioneogenesis and worse prognosis.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: July 2018

Detailed Description

Hepatocellular carcinoma (HCC) represents the commonest primary cancer of the liver. Incidence is increasing and HCC has risen to become the 5th commonest malignancy worldwide and the third leading cause of cancer related death, exceeded only by cancers of the lung and stomach. HCC prevalence is higher in sub-Saharan Africa, central and Southeast Asia.Serum lactate dehydrogenase (LDH) levels is an indirect marker of tumor hypoxia, angioneogenesis and worse prognosis. Lactic dehydrogenase (LDH), which is a glycolytic enzyme, composed of four polypeptide chains, each one encoded by separate gene (M and H), exists in various types of human tissue and neoplasms. LDH is a key enzyme in the conversion pyruvate to lactate under anaerobic conditions .Five isoforms of LDH have been identified as a result of the five different combinations of polypeptide subunits. Hypoxia represents a clinical biological mechanism for treatment resistance in cancer cells via the formation of new blood vessels. Furthermore, a growing body of evidence indicates that hypoxia might actually promote cancer development.

Interventions

  • Other: LDH serum level
    • Blood sample to measure LDH as a predictor of Hepatocellular carcinoma treatment outcome

Arms, Groups and Cohorts

  • Group A
    • Patients with Hepatocellular carcinoma who treated with sorafenib and measure LDH serum level one month pre and post treatment
  • Group B
    • Patients with Hepatocellular carcinoma who treated with trans catheter arterial chemo embolization (TACE) and measure LDH serum level one month pre and post treatment
  • Group C
    • Patients with Hepatocellular carcinoma who treated surgically and measure LDH serum level one month pre and post treatment
  • Group D
    • Patients with Hepatocellular carcinoma who don’t receive treatment and asses LDH serum level for 3months

Clinical Trial Outcome Measures

Primary Measures

  • serum LDH level as a predictor of response in hepatocellular carcinoma
    • Time Frame: 2 months
    • To evaluate if serum LDH level can be used as a predictor of response in patients receiving different lines of treatment for hepatocellular carcinoma

Participating in This Clinical Trial

Inclusion Criteria

  • patients with Hepatocellular carcinoma diagnosed by biopsy or imaging criteria and alpha feto protein. – signed informed consent before registration in study – Eastern Cooperative oncology Groups Performance status between 0 and 2. Exclusion Criteria:

  • Cachexia or poor condition – pregnant or human chorionic gonadotropin positive – patient with another liver tumor – Any previous treatment

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Assiut University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Nourhan Yousef, Principal Investigator – Assiut University
  • Overall Official(s)
    • Aml R Ibrahim, Lecturer, Principal Investigator, Assiut University
  • Overall Contact(s)
    • Samir S Mohammed, Professor, 00201222302375, samir_eid@hotmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.